皮下注射贝利尤单抗序贯一个周期利妥昔单抗治疗系统性红斑狼疮患者的疗效与安全性:3期随机安慰剂对照BLISS-BELIEVE研究
BLISS-BELIEVE研究为3期双盲随机对照试验,纳入活动性SLE患者,在启动皮下贝利尤单抗200 mg/周治疗52周基础上,比较联合一个周期利妥昔单抗与安慰剂在第52周疾病控制率等方面的差异。结果显示两组第52周疾病控制率无统计学显著差异,主要次要终点亦无统计学显著差异,但BEL/RTX组抗dsDNA抗体及多数B细胞亚群水平低于BEL/PBO组,且第52周内平均疾病控制持续时间显著更长。
要点
- 第52周疾病控制率BEL/PBO组16.7%(12/72)vs BEL/RTX组19.4%(28/144),OR 1.27(95%CI 0.60至2.71),p=0.5342,无统计学显著差异。
- 主要次要终点(第64周临床缓解、第104周疾病控制)两组差异均无统计学显著差异。
- BEL/RTX组抗dsDNA抗体及多数评估的B细胞/B细胞亚群低于BEL/PBO组,第52周内平均疾病控制持续时间显著更长。
核心结论
- BEL/RTX在多数分析终点上未显示出优于BEL/PBO,但与BEL/PBO相比在疾病活动标志物方面带来显著改善。
- 作者认为有必要进一步研究联合治疗。
研究设计与样本
- 3期双盲BLISS-BELIEVE试验(GSK研究205646),患者为活动性SLE,启动皮下贝利尤单抗200 mg/周治疗52周。
- 患者随机接受静脉安慰剂(BEL/PBO)或静脉利妥昔单抗1000 mg(BEL/RTX),分别在第4周和第6周给药,同时停用合并免疫抑制剂/逐渐减量糖皮质激素。
- 研究包含标准治疗104周的参考臂(BEL/ST)。
- 改良意向治疗人群共263例患者。
主要发现
- 第52周达到疾病控制(SLEDAI-2K≤2、未用免疫抑制剂、泼尼松等效剂量≤5 mg/天)的比例:BEL/PBO组16.7%(12/72)vs BEL/RTX组19.4%(28/144),OR 1.27(95%CI 0.60至2.71),p=0.5342。
- 主要次要终点方面,BEL/RTX与BEL/PBO之间的差异无统计学显著差异。
- BEL/RTX组抗dsDNA抗体及多数评估的B细胞/B细胞亚群低于BEL/PBO组。
- 第52周内平均疾病控制持续时间BEL/RTX组显著长于BEL/PBO组。
关键数值与推荐
- 主要终点:第52周疾病控制比例,定义为SLEDAI-2K≤2、未用免疫抑制剂、泼尼松等效剂量≤5 mg/天,比较BEL/RTX与BEL/PBO。
- 主要(α控制)次要终点:第64周临床缓解比例(临床SLEDAI-2K=0、未用免疫抑制剂/糖皮质激素);第104周疾病控制比例。
- 其他评估:疾病控制持续时间、抗dsDNA抗体、C3/C4及B细胞/B细胞亚群。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为有必要进一步研究联合治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Disease activity control in patients with systemic lupus erythematosus (SLE) with corticosteroid and immunosuppressant withdrawal is a treatment goal. We evaluated whether this could be attained with sequential subcutaneous belimumab (BEL) and one cycle of rituximab (RTX). METHODS: In this phase 3, double-blind BLISS-BELIEVE trial (GSK Study 205646), patients with active SLE initiating subcutaneous BEL 200 mg/week for 52 weeks were randomised to intravenous placebo (BEL/PBO) or intravenous RTX 1000 mg (BEL/RTX) at weeks 4 and 6 while stopping concomitant immunosuppressants/tapering corticosteroids; standard therapy for 104 weeks (BEL/ST; reference arm) was included. PRIMARY ENDPOINT: proportion of patients achieving disease control (SLE Disease Activity Index-2000 (SLEDAI-2K) ≤2; without immunosuppressants; prednisone equivalent ≤5 mg/day) at week 52 with BEL/RTX versus BEL/PBO. Major (alpha-controlled) secondary endpoints: proportion of patients with clinical remission (week 64; clinical SLEDAI-2K=0, without immunosuppressants/corticosteroids); proportion of patients with disease control (week 104). Other assessments: disease control duration, anti-dsDNA antibody, C3/C4 and B cells/B-cell subsets. RESULTS: The modified intention-to-treat population included 263 patients. Overall, 16.7% (12/72) of BEL/PBO and 19.4% (28/144) of BEL/RTX patients achieved disease control (OR (95% CI) 1.27 (0.60 to 2.71); p=0.5342) at week 52. For major secondary endpoints, differences between BEL/RTX and BEL/PBO were not statistically significant. Anti-dsDNA antibodies and most assessed B cells/B-cell subsets were lower with BEL/RTX versus BEL/PBO. Mean disease control duration through 52 weeks was significantly greater with BEL/RTX versus BEL/PBO. CONCLUSIONS: BEL/RTX showed no superiority over BEL/PBO for most endpoints analysed; however, it led to significant improvements in disease activity markers compared with BEL/PBO. Further investigation of combination treatment is warranted. TRIAL REGISTRATION NUMBER: NCT03312907.
引用
- Aranow C, Allaart CF, Amoura Z, et al. Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study. Ann Rheum Dis. 2024. PMID: 39159997. doi:10.1136/ard-2024-225686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。